JPRN-UMIN000027270招募中未知
A study on Prevention of Hypertensive Disorders of Pregnancy who have a history of severe hypertensive disorders of pregnancy -Pre-test for multi center trial
Mie university hospital, Department of Obstetrics and Gynecology0 个研究点目标入组 20 人开始时间: 2017年5月15日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable(—)
- 性别
- Female
入选标准
- •1) 20 years of age or older
- •2) History of severe Hypertensive disorders of Pregnancy that required delivery prior to 34 weeks' gestation.
- •3) Gestational age between 12 + 0 and 16 + 6 weeks (The expected date of confinement is determined using the criteria of the guidelines for obstetrical practice in Japan 2014.)
- •4) Singleton pregnancy
- •5) For the test participation, it has consent is obtained in writing from the patient.
排除标准
- •1)A history of allergy to tadalafil
- •2)Concurrent medications that interact adversely with tadalafil
- •3)Relative contraindication of tadalafil treatment due to renal disease.
- •4)Relative contraindication of tadalafil treatment due to liver disease.
- •5)Relative contraindication of tadalafil treatment due to uncontrolled arrhythmia, hypertension (BP >170/110 mmHg), and hypotension (BP <80/40 mmHg).
- •6)Fetus with suspected chromosomal disorder and/or multiple congenital anomalies.
- •7)Relative contraindication of tadalafil treatment due to retinitis pigmentosa, coagulation defect, active gastric and/or intestinal ulcer, and venous obstructive disease.
- •8)Attending physician decides to entry inappropriate.
研究者
相似试验
进行中(未招募)
不适用
Prevention for Recurrence Of The preEClampsia with TAdalafilJPRN-jRCTs041180121Tanaka Hiroaki20
尚未招募
1 期
aotai Fang for prevention and treatment of hypertensive cerebral small vessel disease: randomized, double-blind, placebo-controlled, multi-center clinical trial protocolITMCTR1900002466Hu'nan University of Chinese Medicine
进行中(未招募)
不适用
Stroke Prevention by Antihypertensive Drugs (SPREAD) TrialCardiovascular - HypertensionStroke -HypertensionACTRN12607000109404Cardiovascular Institute, Chinese Academy of Medical Sciences6,000
进行中(未招募)
不适用
Prevención de la progresión de la hipertensión portal en la cirrosis compensada mediante el uso de vasodilatadores hepáticos selectivos. Estudio multicéntrico, aleatorizado y doble-ciego - SIMPROEl objetivo de estudio es valorar el efecto de las estatinas, en su efecto vasodilatador selectivo hepático, en la prevención de la progresión de la hipertensión portal ( con un gradiente de presión entre 6 y 10 mmHg) en pacientes con cirrosis hepática compensada.MedDRA version: 12.1Level: HLTClassification code 10036201Term: Portal hypertensionsEUCTR2010-021593-11-ESINSTITUT DE RESERCA.HSCSP
已完成
不适用
Hypertension and coronary prevention research projectCirculatory SystemEssential (primary) hypertensionHypertensionISRCTN81113179Department of Health (UK)700
